Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


Last --
Change Today 0.00 / 0.00%
Volume 0.0
3933 On Other Exchanges
Symbol
Exchange
3933 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

the united laboratories inte (3933) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THE UNITED LABORATORIES INTE (3933)

Related News

No related news articles were found.

the united laboratories inte (3933) Related Businessweek News

No Related Businessweek News Found

the united laboratories inte (3933) Details

The United Laboratories International Holdings Limited, an investment holding company, manufactures and sells pharmaceutical products. The company operates in three segments: Intermediate Products, Bulk Medicine, and Finished Products. It offers antibiotic and non-antibiotic finished products, and soft capsules casings. The company also produces and sells bulk medicine, pharmaceutical intermediate products, and organic fertilizers. In addition, it engages in trading pharmaceutical products. The company operates primarily in the People's Republic of China, Europe, India, the Middle East, South America, and other Asian regions. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. The United Laboratories International Holdings Limited is a subsidiary of Heren Far East Limited.

12,000 Employees
Last Reported Date: 09/23/15
Founded in 1990

the united laboratories inte (3933) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $4.0M
Vice Chairman, Chief Financial Officer and Co...
Total Annual Compensation: $3.7M
Vice President, General Manager of China Sale...
Total Annual Compensation: $2.7M
Vice President and Executive Director
Total Annual Compensation: $2.7M
Vice President and Executive Director
Total Annual Compensation: $2.7M
Compensation as of Fiscal Year 2014.

the united laboratories inte (3933) Key Developments

The United Laboratories International Holdings Limited Announces Unaudited Consolidated Cash Flow Results for the Six Months Ended June 30, 2015

The United Laboratories International Holdings Limited announced unaudited consolidated cash flow results for the six months ended June 30, 2015. For the period, the company reported net cash from operating activities of HKD 1,118,516,000 against HKD 967,778,000 a year ago. Payments for purchase of property, plant and equipment was HKD 377,723,000 against HKD 301,458,000 a year ago. Additions to intangible assets were HKD 27,404,000.

The United Laboratories International Holdings Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

The United Laboratories International Holdings Limited announced unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenue of HKD 4,062,365,000, profit before taxation of HKD 259,380,000, profit attributable to owners of the company of HKD 280,279,000 or HKD 17.23 per diluted share compared to the revenue of HKD 3,701,221,000, profit before taxation of HKD 790,413,000, profit attributable to owners of the company of HKD 709,906,000 or HKD 43.64 per diluted share a year ago. EBITDA was HKD 803,364,000 against HKD 1,283,137,000 a year ago.

The United Laboratories International Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2015

The United Laboratories International Holdings Limited provided earnings guidance for the six months ended June 30, 2015. For the period, the group is expected to record a substantial decrease in profit to not less than approximately HKD 250,000,000, while the net profit for the six months ended 30 June 2014 is approximately HKD 710,000,000. The decrease in profit is mainly attributable to: One-off subsidy income from the local government of approximately HKD 390,000,000 was received during the corresponding period in last year but there is no such income during current period; and the fair value of the investment properties in Chengdu decreased as at 30 June 2015 compared with last year as the real estate market in China continued to be sluggish during the period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3933:HK $3.04 HKD -0.02

3933 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3933.
View Industry Companies
 

Industry Analysis

3933

Industry Average

Valuation 3933 Industry Range
Price/Earnings 19.6x
Price/Sales 0.6x
Price/Book 0.7x
Price/Cash Flow 19.6x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact THE UNITED LABORATORIES INTE, please visit www.tul.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.